iPCS Cell Modeling of Inherited Cardiac Arrhythmias
- 577 Downloads
The study of inherited cardiac disorders is hampered by the lack of suitable in vitro human cardiac disease models and relevant functional assays. A potential solution to this cell-sourcing challenge may be the recently described human induced pluripotent stem cell (hiPSC) technology. Pioneering studies were successful in establishing patient-specific, hiPSC-derived cardiomyocyte models of the most common inherited cardiac arrhythmogenic disorders, such as the different long QT syndrome subtypes (types 1, 2, 3, 8), overlap syndrome LQTS3/Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT) types 1 and 2, and arrhythmogenic right ventricular cardiomyopathy (ARVC). These studies initially demonstrated the ability of the generated hiPSC models to recapitulate the disease processes in the culture dish. More recently, such studies were also able to provide new mechanistic insights into the disease processes, as well as to derive a unique drug-screening platform to test existing and novel therapeutic treatment options in an environment resembling the human physiological milieu. Moreover, initial evidence suggests that such models can help to optimize drug treatment in a personalized manner in the future. Nevertheless, several hurdles still exist for using hiPSC-based models for the aforementioned tasks, such as the hiPSC-derived cardiomyocytes’ relatively immature phenotype, and also the resulting cell heterogeneity. Extensive research work is ongoing to address these challenges, as well as to add new opportunities for the field by utilizing recent advances in gene editing technologies. Here, we discuss the significant findings that hiPSC-based models have provided for each of the inherited cardiac arrhythmia syndromes so far, and the current challenges that this technique is facing.
KeywordsDisease modeling Induced pluripotent stem cells Long QT syndrome Catecholaminergic polymorphic ventricular tachycardia Inherited cardiac arrhythmias Cardiomyocytes Arrhythmogenic right ventricular cardiomyopathy
This study was funded in part by the European Research Council Ideas program [ERC-2010-StG-260830-Cardio-iPS], by the Nancy & Stephen Grand Philanthropic Fund, and the Wingarten estate fund.
Compliance with Ethics Guidelines
Conflict of Interest
MSc Rami Shinnawi and Dr. Lior Gepstein each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Moretti A, Laugwitz KL, Dorn T, Sinnecker D, Mummery C. Pluripotent stem cell models of human heart disease. Cold Spring Harb Perspect Med. 2013;3(11). doi: 10.1101/cshperspect.a014027
- 5.••Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72. Revolutionary study describing that mature somatic cells can be reprogrammed into pluripotent stem cells by introducing a set of transcription factors.PubMedCrossRefGoogle Scholar
- 9.••Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010;363(15):1397–409. The first study demonstrating that hiPSC-derived cardiomyocytes from a patient carrying inherited cardiac arrythmia can recapitulate the patient's disease phenotype.PubMedCrossRefGoogle Scholar
- 11.••Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011;471(7337):225–9. Pioneering study demonstrating that hiPSC-CMs derived from healthy and diseased patients could serve for drug testing ameliorating or aggravating disease phenotype, both at the single and multicellular level.PubMedCrossRefGoogle Scholar
- 12.•Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J. 2013. doi: 10.1038/emboj.2013.240. Description of the use of an isogenic control line, by correcting the causative mutation, as an optimal control since it eliminates patient-specific genetic background differences between the control and the diseased cells.
- 13.Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J. 2011;32(8):952–62. doi: 10.1093/eurheartj/ehr073.PubMedCentralPubMedCrossRefGoogle Scholar
- 18.Davis RP, Casini S, van den Berg CW, Hoekstra M, Remme CA, Dambrot C, et al. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation. 2012;125(25):3079–91. doi: 10.1161/CIRCULATIONAHA.111.066092.PubMedCrossRefGoogle Scholar
- 19.Jung CB, Moretti A. Mederos y Schnitzler M, Iop L, Storch U, Bellin M et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO. Mol Med. 2012;4(3):180–91.Google Scholar
- 22.Kujala K, Paavola J, Lahti A, Larsson K, Pekkanen-Mattila M, Viitasalo M, et al. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations. PLoS One. 2012;7(9):e44660. doi: 10.1371/journal.pone.0044660.PubMedCentralPubMedCrossRefGoogle Scholar
- 23.Di Pasquale E, Lodola F, Miragoli M, Denegri M, Avelino-Cruz JE, Buonocore M, et al. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis. 2013;4:e843. doi: 10.1038/cddis.2013.369.PubMedCentralPubMedCrossRefGoogle Scholar
- 27.Ma D, Wei H, Lu J, Ho S, Zhang G, Sun X, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2013;34:1122–33.Google Scholar
- 33.Zhang H, Zou B, Yu H, Moretti A, Wang X, Yan W, et al. Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. Proc Natl Acad Sci U S A. 2012;109(29):11866–71. doi: 10.1073/pnas.1205266109.PubMedCentralPubMedCrossRefGoogle Scholar
- 37.Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013;127(16):1677–91. doi: 10.1161/CIRCULATIONAHA.113.001883.PubMedCrossRefGoogle Scholar
- 41.Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69(6):1378–84. doi: 10.1086/324565.PubMedCentralPubMedCrossRefGoogle Scholar
- 42.Zhang XH, Haviland S, Wei H, Saric T, Fatima A, Hescheler J, et al. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. Cell Calcium. 2013;54(2):57–70. doi: 10.1016/j.ceca.2013.04.004.PubMedCentralPubMedCrossRefGoogle Scholar
- 49.Bett GC, Kaplan AD, Lis A, Cimato TR, Tzanakakis ES, Zhou Q et al. Electronic "expression" of the inward rectifier in cardiocytes derived from human-induced pluripotent stem cells. Heart Rhythm. 2013. doi:S1547-5271(13)01071-0.Google Scholar
- 50.Halbach M, Peinkofer G, Baumgartner S, Maass M, Wiedey M, Neef K et al. Electrophysiological integration and action potential properties of transplanted cardiomyocytes derived from induced pluripotent stem cells. Cardiovasc Res. 2013. doi:cvt213.Google Scholar
- 55.Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A. 2012;109(27):E1848–57. doi: 10.1073/pnas.1200250109.PubMedCentralPubMedCrossRefGoogle Scholar
- 56.Lian X, Zhang J, Azarin SM, Zhu K, Hazeltine LB, Bao X, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat Protoc. 2013;8(1):162–75. doi: 10.1038/nprot.2012.150.PubMedCentralPubMedCrossRefGoogle Scholar